Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 28;30(24):3120-3122.
doi: 10.3748/wjg.v30.i24.3120.

Managing immune checkpoint inhibitor-associated gastritis: Insights and strategies

Li-Li Yu  1   2 , Zhi-Lin He  1   3 , Xin-Lai Qian  1   3
Affiliations
Review

Managing immune checkpoint inhibitor-associated gastritis: Insights and strategies

Li-Li Yu et al. World J Gastroenterol. .

Abstract

Immune checkpoint inhibitors (ICIs) are widely used due to their effectiveness in treating various tumors. Immune-related adverse events (irAEs) are defined as adverse effects resulting from ICI treatment. Gastrointestinal irAEs are a common type of irAEs characterized by intestinal side effects, such as diarrhea and colitis, which may lead to the discontinuation of ICIs.

Keywords: Autoimmune responses; Immune checkpoint inhibitor; Immune checkpoint inhibitor-related gastritis; Immune-related adverse events; Immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
A common mechanism by which immune checkpoint inhibitors exert their effects involves activation of effector T cells by inhibition of programmed death 1, programmed death-ligand 1, and cytotoxic T-lymphocyte antigen 4. ICI: Immune checkpoint inhibitor; PD-1: Programmed death 1; PD-L1: Programmed death-ligand 1; CTLA-4: Cytotoxic T-lymphocyte antigen 4; irAEs: Immune-related adverse events.
See this image and copyright information in PMC

References

    1. Lin J, Lin ZQ, Zheng SC, Chen Y. Immune checkpoint inhibitor-associated gastritis: Patterns and management. World J Gastroenterol. 2024;30:1941–1948. - PMC - PubMed
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. - PMC - PubMed
    1. Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18:87. - PMC - PubMed
    1. Rao BB, Robertson S, Philpott J. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab. Am J Gastroenterol. 2019;114:196. - PubMed
    1. Nishimura Y, Yasuda M, Ocho K, Iwamuro M, Yamasaki O, Tanaka T, Otsuka F. Severe Gastritis after Administration of Nivolumab and Ipilimumab. Case Rep Oncol. 2018;11:549–556. - PMC - PubMed

Substances

LinkOut - more resources